Cynata Therapeutics Limited (ASX:CYP) published its Annual Report for the year ended 30 June 2026, with the directors' report signed in Melbourne on 28 September 2026. The group reported a loss of $9,248,815, compared with $9,390,586 in FY2025, a reduction of about 1.5%. Cash and cash equivalents fell to $897,418 from $5,049,744, and the Balance Sheet moved from net Assets of $5,981,735 to net liabilities of $553,774.

The year was dominated by two clinical readouts in June 2026. The Phase 2 trial of CYP-001 in acute graft versus host disease and the Phase 3 SCUlpTOR trial of CYP-004 in knee osteoarthritis both failed to show a benefit over control. On 6 July 2026 the company then restructured, making every employee position redundant. This article sets out the figures and the developments behind them.

Company Overview

Cynata develops products from Cymerus, a proprietary platform that uses induced pluripotent stem cells to manufacture mesenchymal stromal cells. According to the chair's letter, the platform offers a way to make these cells at commercial scale from a single, consistent cell source. The company is based in Cremorne, Victoria, and is now managed directly by its board, chaired by Dr Geoff Brooke, with Dr Kilian Kelly, the former Managing Director and Chief Executive Officer, remaining as an unpaid non-executive director.

Cynata does not generate operating revenue. Its income consists of interest and the Australian Government's Research and Development Tax Incentive rebate, and its core intellectual property is partly licensed from the Wisconsin Alumni Research Foundation and Cellular Dynamics International, which carry ongoing milestone and Royalty obligations.

Details of the FY2026 Annual Report

Total revenue and other income fell to $1,791,103 from $2,112,839. The R&D rebate was $1,711,618 (FY2025: $1,885,140) and interest income was $79,485 (FY2025: $227,699). On the cost side, product development costs fell to $5,540,832 from $7,398,004, employee benefits fell to $1,848,277 from $2,067,760, Amortisation fell to $260,313 from $282,964 and share-based payments fell to $129,930 from $260,415. Against those decreases, other expenses rose to $1,906,940 from $1,494,282, and the company recorded an Impairment expense of $1,353,626, compared with nil a year earlier. Loss per share was 3.91 cents against 4.58 cents.

Net operating cash outflow was $6,735,676 (FY2025: $8,720,335), and the company raised $2,704,000 before costs through its at-the-market Facility and a placement, against $8,136,935 in proceeds the year before. Intangibles fell to $234,965 from $1,848,904, and Working Capital moved to a Deficit of $788,739 from a surplus of $4,132,831. Total liabilities rose to $1,908,375 from $1,216,181, including a rise in provisions to $731,850. The company also recognised an additional accrual after agreeing in principle the amount payable to the contract research organisation that ran the Phase 2 trial.

On 17 June 2026 Cynata announced the primary results of the Phase 2 trial, which enrolled 65 patients with high-risk acute graft versus host disease across Australia, the United States and Europe. There were no safety concerns and a similar adverse event profile between groups, but no significant differences in primary or key secondary efficacy endpoints between CYP-001 plus steroids and placebo plus steroids. The company terminated the trial early rather than continue the follow-up period.

On 19 June 2026 it reported that the University of Sydney-led SCUlpTOR trial of CYP-004 did not reach statistical significance on either co-primary endpoint, pain reduction or change in cartilage thickness at 24 months. Knee pain fell substantially and durably from baseline in both groups, which the chair described as an unexpectedly large placebo response, but there were no significant differences between groups at any timepoint.

One programme continues. The investigator-led Phase 1/2 NEREID kidney transplant trial at Leiden University Medical Center completed a positive review of its first cohort of three patients by the independent data safety monitoring board on 4 December 2025, with no rejection episodes and no safety concerns. Enrolment of a second cohort, in which three patients receive two infusions each, is under way. The company also reported new Patent grants and allowances in the United States and Europe.

After year end, on 6 July 2026, Cynata announced that all employee positions were made redundant, including those of the Chief Executive Officer, Chief Medical Officer and Chief Business Officer, that Dr Darryl Maher had resigned as a director, and that the remaining directors had waived their fees from 1 July 2026. It also entered a $600,000 Loan facility secured against its anticipated FY2026 R&D rebate of about $1.7 million, lifting cash to approximately $1.5 million in early July 2026. The company expects about $1 million more once the rebate is received and the loan repaid, and says its forecast runway extends beyond the end of the 2027 financial year.

Industry Context

Cell therapy developers depend on Clinical Trials to show benefit over standard care, and the report illustrates how a placebo group can respond in ways that narrow the measured difference, as in the osteoarthritis study. Neither trial raised new safety concerns, a point the chair stressed, but the efficacy outcomes led the company to conclude that the programmes cannot be developed further in their current form.

The board says it is now evaluating Options for the Cymerus technology, including seeking opportunities to realise its value and to acquire or in-license new assets. That path depends on third-party interest, which the company itself acknowledges may be affected by the recent results.

Risks and Uncertainties

The Going Concern note states that negative working capital, limited financial resources, existing contractual obligations and dependence on additional funding indicate a material uncertainty that may cast significant doubt on the group's ability to continue as a going concern. Directors nonetheless consider there are reasonable grounds to believe it can continue.

The report lists further risks: funding and dilution from any Equity raising, the challenge of identifying and securing new assets, the outcome of the kidney transplant trial, licence obligations, reliance on directors and external advisers now that there are no employees, and the absence of in-house Manufacturing capability.

What to Watch Ahead

Items to follow include the second cohort of the NEREID trial, receipt of the FY2026 R&D rebate and repayment of the loan, and any board announcement on the future of Cymerus or on new assets.